Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ticagrelor (Primary) ; Aspirin
Indications Acute coronary syndromes; Coronary artery disease; Vascular graft occlusion
Focus Therapeutic Use
Acronyms POPular CABG

31 Aug 2020 Primary endpoint (Saphenous vein graft occlusion) has not been met according to the results published in the Circulation
31 Aug 2020 Results published in the Circulation
16 Mar 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com